Related references
Note: Only part of the references are listed.New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects
Guadalupe Aparicio-Gallego et al.
MOLECULAR CANCER THERAPEUTICS (2011)
HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand-Foot Syndrome
Vincent Sibaud et al.
ONCOLOGIST (2011)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma
Chih-Hsun Yang et al.
EXPERT OPINION ON DRUG SAFETY (2010)
The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
Changhoon Yoo et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma
Benoit Blanchet et al.
CLINICA CHIMICA ACTA (2009)
Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
David Chu et al.
CLINICAL GENITOURINARY CANCER (2009)
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma
Fabienne Thomas et al.
EUROPEAN JOURNAL OF CANCER (2009)
A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma
Marie-Christine Etienne-Grimaldi et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
M. E. Lacouture et al.
ANNALS OF ONCOLOGY (2008)
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Mario E. Lacouture et al.
ONCOLOGIST (2008)
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
S. E. Rosenbaum et al.
SUPPORTIVE CARE IN CANCER (2008)
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
C. Porta et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma
Kun-Ying Tsai et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cutaneous side-effects of kinase inhibitors and blocking antibodies
C Robert et al.
LANCET ONCOLOGY (2005)
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Share Paper
